Other studies that have compared biomarkers for prognosis in COVID-19 have used samples from the time of admission, emergency department presentation or unspecified time and have not found significant differences in performance with PCT or CRP, while ours has used samples collected at multiple times, including in the late phase of disease [2, 8]. This evidence concerns the gene CRP and COVID-19.